dm+d

Unassigned

New Medicines

Female infertility - as an adjunct to IVF or ICSI

Information

New molecular entity
ObsEva SA

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Nov 19ObsEva announce discontinuation of PIII IMPLANT 4 trial (n=807) as primary endpoint of increase in ongoing pregnancy rate at 10 weeks was not met [5].

Category

Oral oxytocin receptor antagonist with potential to decrease uterine contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation
About 1 in 7 couples can have some problems conceiving a baby, some of whom will go on to have assisted conception.[1]
Female infertility - as an adjunct to IVF or ICSI
Oral